A monoclonal antibody activating AdipoR for type 2 diabetes and nonalcoholic steatohepatitis

• Published in: Science advances Vol. 9; no. 45; p. eadg4216
• Main Authors: Asahara, Naomi, Okada-Iwabu, Miki, Iwabu, Masato, Wada, Kouichi, Oka, Kozo, Yamauchi, Toshimasa, Kadowaki, Takashi
• Format: Journal Article
• Language: English
• Published: American Association for the Advancement of Science 10.11.2023
• Subjects: Biomedicine and Life Sciences; Diseases and Disorders; SciAdv r-articles
• ISSN: 2375-2548; 2375-2548
• DOI: 10.1126/sciadv.adg4216

Adiponectin receptors, AdipoR1 and AdipoR2 are promising targets for the prevention and treatment of metabolic diseases. In this study, we aimed to establish agonistic antibodies against AdipoR1 and AdipoR2 with a long enough half-life to provide a means of improving poor medication adherence associated with preclinical small-molecule AdipoR agonists or existing antidiabetic drugs. Monoclonal antibodies were obtained by immunizing AdipoR knockout mice with human AdipoR-expressing cells. Of the antibodies shown to bind to both, an agonist antibody was obtained, which exhibited adenosine 5′-monophosphate–activated protein kinase–activating properties such as adiponectin and was named AdipoR-activating monoclonal antibody (AdipoRaMab). AdipoRaMab ameliorated glucose intolerance in high-fat diet–fed mice, which was not observed in AdipoR1·AdipoR2 double knockout mice. AdipoRaMab exhibited anti-inflammatory and antifibrotic effects in the nonalcoholic steatohepatitis (NASH) model, indicating its therapeutic potential in diabetes and in NASH. In addition, the results of this study indicated that AdipoRaMab may exert therapeutic effects even in a once-monthly dosing regimen through its humanization. The AdipoR-activating antibody has the potential to exert therapeutic effects on diabetes and NASH even in a once-monthly dosing.